Media coverage
17
Media coverage
Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet PipelineReview Country/Territory Spain Date 26/06/21 URL https://pipelinereview.com/index.php/2021062678549/Antibodies/Libtayo-cemiplimab-Approved-by-the-European-Commission-as-the-First-Immunotherapy-Indicated-for-Patients-with-Advanced-Basal-Cell-Carcinoma.html Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression Media name/outlet PipelineReview Country/Territory Spain Date 26/06/21 URL https://pipelinereview.com/index.php/2021062678548/Antibodies/Libtayo-cemiplimab-Approved-by-the-European-Commission-for-First-Line-Treatment-of-Patients-with-Advanced-Non-small-Cell-Lung-Cancer-with-%E2%89%A550-PD-L1-Expression.html Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression Media name/outlet PR Newswire Country/Territory United States Date 25/06/21 Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet PR Newswire Country/Territory United States Date 25/06/21 Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 25/06/21 Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 25/06/21 Persons Israel Lowy, Title Sanofi: Libtayo (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 25/06/21 Persons Israel Lowy, Title Sanofi: Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 25/06/21 Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet Crwe World Country/Territory United States Date 25/06/21 URL crweworld.com/article/news-provided-by-pr-newswire/2043405/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet Spoke.com Country/Territory United States Date 25/06/21 URL https://www.spoke.com/press_releases/60d571c1305335cc220177b4 Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet Canadian Insider Country/Territory Canada Date 25/06/21 URL https://www.canadianinsider.com/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet BioSpace Country/Territory United States Date 25/06/21 URL https://www.biospace.com/article/releases/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma/ Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression Media name/outlet BioSpace Country/Territory United States Date 25/06/21 URL https://www.biospace.com/article/releases/libtayo-cemiplimab-approved-by-the-european-commission-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-50-percent-pd-l1-expression/?s=95 Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet Biotechgate Country/Territory Switzerland Date 25/06/21 URL www.biotechgate.com/gate/v3/news_details.php?news_id=253120&page_id=?next=1 Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression Media name/outlet VB Profiles Country/Territory United States Date 25/06/21 URL https://www.vbprofiles.com/press_releases/60d56fbeb9abe45dbc6661a9 Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet VB Profiles Country/Territory United States Date 25/06/21 URL https://www.vbprofiles.com/press_releases/60d56fbeb9abe45dbc6661ad Persons Israel Lowy, Title Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Media name/outlet Regeneron Country/Territory United States Date 25/06/21 URL https://newsroom.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-approved-european-commission-first Persons Israel Lowy,